Transcat (NASDAQ:TRNS) Posts Quarterly Earnings Results

Transcat (NASDAQ:TRNS) released its quarterly earnings data on Tuesday. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.19, FiscalAI reports. Transcat had a net margin of 0.99% and a return on equity of 5.56%. The company had revenue of $97.09 million during the quarter, compared to analyst estimates of $92.46 million.

Here are the key takeaways from Transcat’s conference call:

• Strong second-quarter growth: Revenue increased 18% to $97.1 million, while adjusted EBITDA rose 23% and adjusted EPS grew 46% to $0.64. Service revenue grew 23%, including 16% organic growth, marking the 70th consecutive quarter of year-over-year service growth.
• Service profitability improved substantially: Service gross margin expanded 220 basis points to 34.4%, helped by operating leverage, pricing, business-mix improvements, and operational-excellence initiatives. Management expects at least 100 basis points of year-over-year service gross-margin expansion in the second half.
• Full-year service outlook was raised: Transcat increased its fiscal 2027 service organic revenue-growth forecast from high single digits to low double digits, citing broad-based demand, market-share gains, improved sales execution, and better visibility into large customer wins.
• Acquisition and rental strategies remain key growth drivers: The Southeastern Biomedical Associates acquisition expands Transcat’s reach in biomedical calibration and hospital networks, while rentals are expected to grow at a low-double-digit rate over time. Distribution margins declined year over year because of lower-margin used-equipment sales, but management expects distribution-margin improvement in the second half.
• Financial capacity supports continued expansion: Operating free cash flow rose 46% to $10.9 million in the first half, while quarter-end debt was $116.9 million, with $33.1 million available under the revolving credit facility and leverage of 2.18 times.

Transcat Price Performance

Shares of Transcat stock traded up $1.60 during mid-day trading on Tuesday, reaching $89.52. 330,569 shares of the stock traded hands, compared to its average volume of 145,243. The business has a 50-day moving average of $86.05 and a 200 day moving average of $81.71. The company has a quick ratio of 2.11, a current ratio of 2.49 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $840.59 million, a PE ratio of 241.95 and a beta of 0.66. Transcat has a fifty-two week low of $50.23 and a fifty-two week high of $100.00.

Insider Activity

In related news, Director Christopher P. Gillette sold 504 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $94.23, for a total transaction of $47,491.92. Following the transaction, the director directly owned 200 shares in the company, valued at approximately $18,846. The trade was a 71.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Craig Cairns purchased 1,050 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $93.97 per share, with a total value of $98,668.50. Following the completion of the transaction, the director directly owned 1,480 shares of the company’s stock, valued at approximately $139,075.60. This represents a 244.19% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 1.80% of the company’s stock.

Wall Street Analysts Forecast Growth

TRNS has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Transcat in a report on Tuesday, August 25th. CJS Securities started coverage on Transcat in a research report on Tuesday, October 27th. They issued an “outperform” rating and a $115.00 price objective for the company. Finally, Northland Securities raised shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price target for the company in a report on Wednesday, October 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $105.00.

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.